Our Leadership

OUR LEADERSHIP

Executive Leadership Team

Eric Venker, MD, PharmD

Chief Executive Officer

Eric Venker, MD, PharmD, is the Chief Executive Officer of Immunovant and has served on the Board of Directors since 2020. He brings more than two decades of clinical practice and operating experience to the company. Dr. Venker also serves as the President of Roivant Sciences, a position he has held since 2018. Dr. Venker first joined Roivant in 2014 and has held various roles of increasing responsibility, including Chief Medical Officer, Chief of Staff to the CEO, and most recently, Chief Operating Officer. Earlier in his career, Dr. Venker was a physician at New York Presbyterian Hospital, Columbia University Medical Center, where he trained in internal medicine. While there, Eric led operational initiatives to improve efficiencies across a large hospital system with $5 billion in annual revenue. Earlier in his career, Eric was a Clinical Pharmacist at Yale-New Haven Hospital. Dr. Venker received his M.D. from the Yale School of Medicine and his Pharm.D. from the St. Louis College of Pharmacy.

Farah Ali, MD, MS

Senior Vice President, Clinical Development

Prior to joining Immunovant, Farah was Vice President, Clinical Development for Rare Disease at Amgen. Previously she was Vice President, Clinical Development at Horizon Therapeutics, specializing in rare and autoimmune diseases. In those roles she led multiple clinical development programs across diverse disease states involving global development in both biologic and small molecules. Across her decade of industry experience, including roles at AbbVie and Baxter Healthcare, she served as a leader within clinical development as well as global medical affairs.

Prior to joining industry, she held a faculty position at Northwestern University, Feinberg School of Medicine where she conducted clinical research in addition to providing patient care. She earned a BA in Molecular and Cell Biology from the University of California, Berkeley and both her MD and a Master’s in Clinical Investigation from Northwestern University. She completed her residency and fellowship training at Northwestern University and is a board-certified Pediatric Nephrologist.

Christine Blodgett

Senior Vice President of Human Resources

Christine brings 20 years of progressive human resources leadership experience across several industries and growth phases, from startups to the Fortune 100. She's spent the majority of her career focused on the biotechnology and pharmaceutical industries. Most recently, as the head of HR at Turnstone Biologics, Christine oversaw the Company’s talent strategy and management, learning and development programs, and all matters relating to Turnstone’s people and culture. Prior to that, Christine served as HR Director at Honeywell and held multiple leadership roles at Bristol-Myers Squibb and Medarex, Inc.

Christine holds a B.S. in Business Administration from The College of New Jersey and earned two certifications: a Strategic Human Resources Practices certification from Cornell University and a Professional in Human Resources (PHR) certification.

Andy Deig, MBA

Senior Vice President Strategic Finance

Prior to joining Immunovant, Andy spent almost 13 years at Eli Lilly & Company where he held numerous roles in different functions across the business, including finance, sales, and value & access. Most recently, Andy served as the national account manager for McKesson and Walmart after leading the commercial integration of Dermira.
Andy earned a B.A. from Wabash College in 2008 with majors in Economics and German and an M.B.A. in health sector management and strategy from Duke’s Fuqua School of Business in 2016.

Khira Gabliani, MBA

Chief of Staff to the CEO

Khira has a decade of experience supporting leadership teams on capital allocation, strategic planning, and growth execution across both public and private markets. Prior to joining Immunovant, she spent five years as a venture and growth equity investor, partnering with founders and executives to scale high-growth companies across software, tech-enabled services, digital healthcare, and healthcare technology. She served on multiple boards and advised leadership on initiatives including capital deployment, operational planning, and M&A execution. Khira began her career at J.P. Morgan in U.S. equity, where she advised institutional investors and corporate clients on public equity transactions, including IPOs and follow-on offerings.

Khira holds an M.B.A. from the MIT Sloan School of Management and a B.S. from Boston College’s Carroll School of Management.

Michael Geffner MD, MBA

Chief Medical Officer

Prior to joining Immunovant, Dr. Geffner was the Chief Medical Officer and head of Product Development for BlueSphere Bio (BSB), an Immuno-Oncology company focused on developing adoptive T-cell therapeutics. Before his role at BSB, he led Hematology Clinical Development for the danicopan development program and was the Head of Global Medical Affairs for Achillion Pharmaceuticals (now Astra Zeneca). Prior to Achillion, he spent 15 years in various senior leadership positions at Schering-Plough/Merck across Clinical Development, Clinical Operations, and Medical Affairs. His other prior roles include, Head of the Anti-infectives/hospital and specialty care Medical Affairs teams, US Medical Affairs integration lead, and Clinical Development Leader.

Dr. Geffner has dual board certification from the American Board of Pediatrics and The American Board of Psychiatry and Neurology, with special competency in Child Neurology. He is a Graduate of Albany Medical College and holds an MBA from Fairleigh Dickinson University

Tiago Girão

Chief Financial Officer

Tiago is a seasoned executive with over 20 years of experience leading finance, accounting, and operations for both public and private companies. Prior to joining Immunovant, Tiago served as the Chief Financial Officer for several Roivant subsidiaries. He was previously the Chief Financial Officer of Cytori Therapeutics, Inc. from 2014 to 2019 and held senior leadership roles at NuVasive, Inc. Tiago began his career in the audit practices of Ernst & Young and KPMG, where he gained over a decade of foundational experience. He also served on the Board of Directors of Landos Biopharma, Inc. from 2021 until its acquisition by AbbVie Inc. in early 2024.

Tiago holds an accounting degree from the Universidade de Fortaleza in Brazil and is a licensed CPA in the state of California.

Melanie Gloria, BSN

Chief Operating Officer

After a successful nursing career, Melanie joined the pharmaceutical industry to fulfill her personal mission to have a broader impact on patients’ lives. Melanie has over 20 years of experience in operational roles in the biotechnology industry. Her experience spans across all phases of development and multiple therapeutic areas. Prior to joining Immunovant, Melanie was the Chief Operating Officer at ACELYRIN where she was responsible for all operational functions and the company’s operating governance. Prior to ACELYRIN Melanie worked at Horizon Therapeutics and led the build out of R&D capabilities. Melanie’s foundational pharmaceutical industry experience started with her time at Abbott and AbbVie. Melanie received her BS in Nursing from University of Illinois, Chicago.

Julie Kirschling

Senior Vice President, Program and Alliance Management

Prior to joining Immunovant, Julie spent 33 years in a variety of project leadership roles at Eli Lilly & Company. She is an experienced project and functional Leader with a proven track record of developing and leading high performing cross-functional teams to enable business critical outcomes and maximizing performance of others with and without direct authority. She has 30+ years of pharmaceutical development experience and 20+ years of experience leading projects across all phases of development and therapeutic areas including leading successful submissions for two marketed products.

She holds a B.S. degree in Chemical Engineering from Purdue University and is a certified Project Management Professional.

Bill Macias, MD, PhD

CMO Emeritus

From 2018 to May 2021, Bill was the Chief Executive Officer at Focus Biomedical Consulting LLC, and in that role was the interim Chief Medical Officer for Promethera Biosciences S.A. from 2019 through 2020. From 1994 through 2017, Bill was at Eli Lilly and Company. At Lilly, he led multiple clinical development programs, leading to the submission and approval of medications across diverse therapeutic areas in both biologic and small molecules. From 2011 onward, he held multiple global development leadership roles in the Biomedicines Business Unit. Prior to joining Eli Lilly and Company, he was an Associate Professor of Medicine at Indiana University School of Medicine.

Bill earned a B.A. in Biology from Marquette University and both an M.D. and Ph.D. from Indiana University School of Medicine. He held board certifications in Internal Medicine, Nephrology, and Critical Care in Medicine.

Becky Merlina

Senior Vice President, Global Head of Quality

Becky Merlina brings extensive Quality leadership experience to her position at Immunovant.

Prior to joining Immunovant, she was the Vice President, Quality & Regulatory Clinical Trials Division, Thermo Fisher Scientific, responsible for leading the global quality & regulatory organization to support their clinical trial division in manufacturing, labelling, packaging, storage, and distribution of IMP, Comparator and Clinical Ancillaries at sites worldwide.

Prior to Thermo Fisher Scientific, she served as Head of R&D Quality for Advanced Accelerator Applications (AAA), a division of Novartis. Becky began her career at Eli Lilly, where she held roles of increasing levels of responsibility, and eventually served as Director of Global Quality Auditing and Compliance.

Becky holds a B.S. Pharmacy degree from Butler University.

Sheetal Patel, MD, MBA, MS

Senior Vice President, Clinical Development

Sheetal is a physician with more than 20 years of experience in academia and the biopharmaceutical industry. She has held key roles in all phases of clinical development, medical affairs, and data generation. She has led cross-functional teams for filing of multiple BLA, NDA and device submissions, bringing multiple products to market. Her skillsets expanse from Phase I-IV, registrations trials, prelaunch, launch and LCM in various therapeutic areas globally. Sheetal has worked across large and small biopharmaceutical companies, including: Baxter, Abbott, Shire, Takeda, Bayer, Exact Sciences, Relmada and Lundbeck. She also held positions at Rush University Medical Center and University of Illinois and other Chicago Hospitals prior to making her transition to industry.

Sheetal received her MD from Medical University of Lublin and a Master of Clinical Research from Rush University. In 2022, Sheetal received her Executive MBA from MIT (Massachusetts Institute of Technology).

Jody Roth, MS

Senior Vice President, Regulatory Affairs

Jody is recognized for her communication and advocacy of label-in-mind concepts, as well as her expertise in FDA interactions. Prior to joining Immunovant, Jody held leadership positions at Outpost Medicine, Gate Neurosciences, and Guidehouse where she set up new molecules for a successful global registration across multiple regions. Prior to roles in biotech, Jody spent 25 years at Eli Lilly and Company established robust filing experience across the drug development lifecycle where she supported the initiation of new molecules and obtaining US approvals for BLAs and NDAs.

Jody has her B.S. in Animal Science and M.S. in Growth Physiology/Immunology from Purdue University. Jody is a member of Regulatory Affairs Professionals and Project Management Institute.

Jay S. Stout, PhD, MS

Chief Technology Officer

Jay is the Chief Technology Officer at Immunovant. From 2020 until April 2023, he was an independent consultant supporting the scale up and validation of late-stage products in immunology and cell and gene therapy. From June 2018 until January 2021, he led the Technical Operations at Immunomedics (Gilead) leading to the approval of an antibody drug conjugate for oncology. Prior to that Jay has held various senior leadership roles in Technical Operation at Versartis (Aravive), San Bio, Merck, Amgen, Pfizer, and BioNebraska (Restoragen). He has a proven track record of Biologic approvals for Monoclonal Antibodies, Antibody Drug Conjugates, and Cell and Gene Therapies.

Jay received a B.S. and M.S. in Chemistry from the University of Iowa and a Ph.D. in Chemistry and Biochemistry from the University of Nebraska-Lincoln. Dr. Stout has served on the Amgen Center for BioProcessing Advisory Board at the Keck Graduate Institute for more than 10 years and was the Chair of the Advisory Board from 2021-2023.

Christopher Van Tuyl, JD

Chief Legal Officer and Corporate Secretary

Chris Van Tuyl brings over 25 years of legal experience to Immunovant. He most recently served as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in Immuno-Dermatology. Prior to joining Dermavant, Mr. Van Tuyl was a corporate partner at the law firm Sacks Tierney P.A., where his practice focused on the healthcare, pharmaceutical, and technology industries. He previously served in various in-house legal positions at publicly traded companies, including as Legal Executive at FIS Global, Corporate Secretary and Chief Compliance Officer at Rayonier Inc., and Associate General Counsel at Medicis Pharmaceutical Corporation. Mr. Van Tuyl began his legal career in private practice as a corporate attorney at the international law firms of Squire, Sanders & Dempsey LLP in Phoenix and Clifford Chance LLP in New York.

He received his J.D. from Duke University School of Law and his B.S. in Finance summa cum laude from Arizona State University.

Yan Zheng, PhD, MS

Senior Vice President Biostatistics, Programming & Data Management

Yan brings more than 16 years of experience with broad knowledge in diverse aspects of drug development, including real-world evidence and medical affairs, microbiome biosciences, and across multiple therapeutic areas. Prior to Immunovant, Yan led biometrics at Kaleido Biosciences, where she built and led the biometrics team and strategic and operational planning of biometric resources and contributions. Prior to Kaleido Biosciences, Yan held roles at Sarepta Therapeutics, Merck, Allergan, and Sanofi.

Yan earned a B.S. in Probability and Statistics from Peking University in China. She has an M.S. and Ph.D. in Biostatistics from the University of Minnesota, Twin Cities.

Senior Management

Maria Alba, MD

Vice President of Clinical Development

Maria has over 16 years of experience across all phases of development in rare disease, endocrinology, and metabolism. Prior to joining Immunovant, Maria was the Global Medical Leader at Amicus Therapeutics for a phase 2 and 3 clinical program for the development of a second-generation enzyme replacement therapy for Pompe disease. Prior to Amicus Therapeutics, Maria held clinical roles at Vertex, Merck, and Janssen Pharmaceuticals.

Maria earned her M.D. from the Catholic University in Rome, Italy, where she also completed her fellowship in endocrinology and metabolism. Maria went on to complete a post-doctoral fellowship for preclinical research on growth hormone deficiency at the Johns Hopkins University.

Jennifer Ashley, JD

Vice President, Associate General Counsel

Jennifer has over 23 years of experience providing legal and business advice for technology and pharmaceutical companies, advising on complex business transaction, product development, and commercialization/compliance matters. She started her career at Cooley LLP, before transitioning to various in-house roles of increasing scope and oversight responsibility. Most recently, Jennifer served as Senior Vice President, Legal for a commercial stage, public biopharma company, overseeing legal support for the in-licensing, development, launch and commercialization of oncology products in multiple indications.

Jennifer holds a B.A. in Biological Sciences and Sociology from Southern Methodist University and a J.D. from The University of Texas School of Law.

Harry Berlanga, MSc

VP, CMC & Distribution Quality

Harry Berlanga brings nearly 25 years of experience as a quality professional to Immunovant. His experience includes large and small molecule manufacturing and packaging and has worked across both commercial and clinical phases.Most recently he managed the quality organization for a contract manufacturing organization producing viral vectors.

He is an experienced UK/EU Qualified Person taking final legal responsibility for the quality of medicines prior to release to market or clinic.

He holds a Masters degree in Pharmaceutical Sciences and a Bachelor’s degree in Biomedical Sciences from the University of Brighton, United Kingdom. He also earned a Masters degree in Strategic Quality Leadership from the University of Portsmouth, United Kingdom.

Thomas Coady

Vice President, Laboratory Quality

Thomas Coady (TC) brings nearly 30 years of experience in numerous roles across analytical and quality in all phases of development and commercialization for both small and large molecule drugs. Prior to joining Immunovant, TC led a 45-member team at a CDMO that provided continuous support for 24/7 manufacturing operations that included microbiology, analytical, raw materials, stability testing, LIMS, and sample logistics management. During his tenure, TC oversaw the implementation LabWare LIMS and SmartQC and defended QC processes and systems for FDA/regulatory inspections, three of which closed without observations. His work with CDMOs provides a unique perspective that is well-suited for CRO, CMO, and CDMO management.

TC holds a Bachelor of Science degree in Biology from Campbell University. TC is a member of the Parenteral Drug Association.

Joel Eksrom, MBA

Vice President, Information Technology

Joel has over 34 years in information system management and leadership experience in the life sciences industry. Prior to joining Immunovant, Joel was the Vice President of Information Technology for Crinetics Pharmaceuticals in San Diego. Before his role at Crinetics, he was the Vice President of IT/Informatics at Ionis Pharmaceuticals and the Vice President of Global R&D IT at Daiichi-Sankyo. Prior to Daiichi-Sankyo he spent over 20 years in various IT senior leadership positions at Roche Pharmaceuticals.

Joel has Bachelor’s degrees in Computer Science and Business Economics from the University of California, Santa Barbara, and MBA from Golden Gate University. He also has a has a Chief Information Security Officer (CISO) certification.

Scott Forman, MBA, MS

Vice President, Program Management

Prior to joining Immunovant, Scott spent over 25 years in the biotech and pharmaceutical industry across several functional and therapeutic areas at Eli Lilly, ICON Clinical Research, Baxter, and, most recently, Horizon Therapeutics and Amgen. His expertise include: cross-functional team leadership, program management, continuous improvement, and corporate business transformation. He has led teams through global regulatory submissions, R&D governance infrastructure build outs, research to clinical transitions, clinical and CMC timeline acceleration initiatives, and an R&D integration resulting from M&A. Scott is an experienced and inclusive ally to all functional areas involved in the drug development process and also is passionate about early career professional development and mentorship.

Scott has a B.S. in Chemistry from Miami University (Ohio), a M.S. in Organic Chemistry from the University of Maryland, and an M.B.A. from the Kelley School of Business at Indiana University.

Tom Forman, MBA

Vice President, CMC Project Management

Tom Forman, MBA spent over 30 years with Eli Lilly where he had numerous roles across Manufacturing, CMC Development, and Portfolio Leadership. He brings over 20 years of experience leading CMC teams in all phases of development from pre-clinical to seeing the successful launch of multiple marketed products. Most recently, he was the early phase portfolio leader for Diabetes and Obesity development.

He holds a BS degree in Chemical Engineering from Purdue University and an MBA with Healthcare focus from the Kelley School of Business at Indiana University. Tom is a registered Project Management Professional.

Dawn Gardner, MBA

Vice President, Program Management

Prior to joining Immunovant, Dawn spent 28 years at Eli Lilly and Company in a variety of clinical supply and project leadership roles in oncology and immunology. Additionally, Dawn has site experience at Indiana University School of Medicine where she established and led a multiple myeloma research program. Most recently, Dawn has worked in the CRO industry as a clinical operations leader. Dawn has a proven track record of developing high performing teams and leading cross-functional teams to achieve high quality, on-time deliverables. Dawn has experience in all phases of development across multiple therapeutic areas including oncology, immunology, neuroscience and women’s health.

Dawn holds a B.S. in Biology and Chemistry from the University of Indianapolis and an MBA from Northeastern University in Boston.

Ian Gourley, MD

Vice President of Clinical Development

Ian is a translational medicine and clinical development physician with over 20 years of experience in the biopharma industry. He has focused on early development of both large and small molecules in the immunology/inflammation space. Prior to joining Immunovant, Ian worked at CSL Behring in Clinical Pharmacology & Translational Development, where he was responsible for strategy and clinical oversight of early development programs in the immunology therapeutic area. Prior to CSL Behring, he held positions as Head of Translational Medicine Science, Immunology, at Janssen and in Clinical Precision Medicine at Pfizer. Ian started his industry career with Eli Lilly as a clinical research pathologist.

Ian received his M.B., B.Ch. and completed his M.D. thesis, both from Queen’s University of Belfast, and is a member of the Royal College of Physicians. He is a board-certified clinical pathologist and is accredited by the American Society for Histocompatibility and Immunogenetics as an HLA laboratory director.

Diane Harper, PhD, JD

Vice President, Regulatory CMC

Diane is a global Regulatory CMC professional who brings with over 25 years of experience to Immunovant. She has had numerous successful health authority interactions and submissions ranging from pre-clinical through registration and post-approval. Prior to joining Immunovant, Diane worked at Merck where she led regulatory-CMC for investigational biologics and small molecule combination programs. For the first 10 years of her career, Diane was a formulations scientist working on lipid nanoparticle delivery systems before transitioning into regulatory affairs, where she has supported monoclonal antibody, peptide, small molecule and vaccine products. Additionally, she has over 12 years of experience in US and EU combination product regulations for prefilled syringes, autoinjectors, nasal sprays, and inhalers.

Diane holds a Ph.D. in Chemistry from the University of Southern California and a J.D. from Emory University School of Law. She also holds a Regulatory Affairs Certificate from the Regulatory Affairs Professional Society.

Laci Hasenour, MBA

Vice President Marketing, Neurology

Laci brings a unique combination of launching new-to-market biotechnology product while also building brands for Fortune 300 companies. Laci's brings 14+ years of experience in biotechnology and healthcare, primarily focusing on specialty therapeutics. She has a proven track record of launching successful brands with go-to-market strategies and market management that leverages sales partnerships and customer insights across diverse product life cycles. Prior to joining Immunovant, Laci's spent 3+ years at Berry Global, a leading B2B sustainable packaging supplier, where she broadened her skills in executive marketing leadership, corporate brand building, and social responsibility initiatives. In her role as VP of Marketing and Corporate Brand Owner, Laci was recognized as Ragan’s 2024 Top Women in Communications. Prior to that, Laci launched a leading dermatology biologic at Eli Lilly and went on to become the senior brand leader.

Laci obtained her BA in Marketing and Economics and an MBA from Xavier University. Laci holds a Sustainability Certificate from the University of Cambridge Institute for Sustainability Leadership.

Aileen Ilaria, MBA

Vice President, Clinical Operations – Global Site Management

Aileen brings an extensive depth of drug development experience in global operations including trial design and execution across a broad array of indications. Prior to joining Immunovant, Aileen was at HUTCHMED International where she was responsible for portfolio and project management and business operations for the execution of the international portfolio. While spending almost 20 years at Eli Lilly and Company, Aileen was a collaborative leader with a proven track record of delivering broad transformational initiatives and excelled in a fast-paced, innovative, and dynamic environment. Before joining Eli Lilly, Aileen worked at several academic medical centers in both clinical and research administration roles.

Aileen holds a B.A in Sociology/Pre-Med from Boston College and an MBA with a concentration in healthcare administration from Boston University.

Claudia Jacobs, PhD

Vice President of CMC Project Management Operations and Clinical Supply

Prior to joining Immunovant Claudia spent over 15 years at Eli Lilly & Company where she held numerous roles in product development in CMC, Clinical Trial Materials Manufacturing and Operations, Clinical Supply and Quality roles, supporting early and late phase program as well as launching products to market. Most recently Claudia was a consultant for biotechnology start-up companies as CMC Project Manager, CMC Development Lead, and Quality Assurance Head for early phase programs small and large molecules.

Claudia obtained her Pharmacy Degree from the University of Hamburg, Germany and earned her Ph.D. in Pharmaceutical Technology from The Free University of Berlin, Germany.

Jonathan Janes, MB BCh

Vice President Clinical Development

Before joining Immunovant, Jonathan held numerous roles working on diabetes, endocrine, and cardiovascular products at Eli Lilly and Company. Between 2009 and 2021 he held various global Medical Director roles, in critical care, immunology and dermatology. While at Eli Lilly he took a lead medical role in the development of both biologic and small molecules leading to successful product submissions and approvals.

Jonathan received a First-Class Honours degree from London University in 1983. Qualifying in Medicine in 1988 from the University of Wales, he trained in the University Hospital of Wales, becoming a Member of the Royal College of Physicians in 1992. In 2005 he was made a Fellow of the Royal College of Physicians of Edinburgh, and in 2021 he also became a Fellow of the Faculty of Pharmaceutical Medicine.

Chedvi Levin-Sister

Vice President of Finance

Chedvi’s expertise includes regulatory compliance (PCAOB, US GAAP, SEC, and IFRS), technical and income tax accounting, revenue recognition (inclusive of gross-to-net in domestic US pharma), stock-based compensation, and leases. She has deep transactional experience in carve-out and business combinations along with implementation of internal controls over financial reporting, including remediation of material weaknesses. Prior to Immunovant, Chedvi spent over 15 years at PwC, where she held numerous roles, most recently as Assurance Director, serving a range of industries and global clients including large pharmaceutical, life science and medical device companies, SEC registrants, technology, and startup companies.

Chedvi earned a B.A. (cum laude) in Management Accounting and Information System from the Jerusalem College of Technology, Israel. She is a CPA (Is).

Launi Masterson

Vice President of Clinical Operations

Launi has more than 25 years of drug development experience in the areas of Global Trial Execution, CRO oversight, client relationship management, vendor management and clinical operations. Prior to Immunovant, Launi led execution of clinical trials at Metavant Sciences, in metabolic disorders. Prior to Metavant, Launi led diverse teams in large pharma, biotech, CROs, and as an entrepreneur managing professionals across a diverse scope in clinical trial planning and delivery.

Launi holds a B.S. degree in Environmental and Biological Sciences from Rutgers University, Cook College.

Andy Minke, MBA

Vice President Program Management

Andy brings over two decades of progressive project leadership experience from pre-clinical to commercialization. He has is a seasoned pharmaceutical project management professional with experience in all phases of global drug and device development. Prior to joining Immunovant, he led efforts at OncoNano Medicine to bring its first therapeutic program to patients with advanced solid tumors and lymphomas. Prior to OncoNano, Andy held positions of increasing responsibility at Galderma, Alcon/Novartis and Bausch & Lomb in project management, quality, and regulatory affairs. He brings over two decades of progressive project leadership experience from pre-clinical to commercialization.

Andy earned a bachelor’s degree from Zuyd University of Applied Sciences in the Netherlands and went on to complete an M.B.A from Harrison College of Business at Southeast Missouri State University.

Linda McKerral, MS

Vice President, CMC Analytical Sciences

Linda joins Immunovant with over 20 years experience in Vaccines and Biologics development and commercialization. Prior to joining, she held various leadership roles overseeing Analytical, Technical Operations and Quality Control functions during her 6 years at Moderna. There, she also led various technical development teams, advancing notable infectious disease vaccine and personalized cancer therapy programs. She scaled analytical development and QC departments to facilitate the company’s rapid growth and evolution. Linda’s career began at Merck and over 15 years she held various technical and leadership roles spanning bioprocess/ analytical development to leading external collaborations. Prior to departing Merck, she was overseeing a large network of CRO’s for pre-/clinical bioanalysis for large molecules, including complex oncology clinical development programs.

Linda holds a Master of Science degree in Microbiology from the University of Guelph, Canada and a Bachelor of Science degree in Biology from the University of Waterloo, Canada. She is a Certified Project Manager (CPM).

Pooja Mehta, MS

Vice President Drug Substance Tech Transfer

Pooja brings over 16 years of experience in biologics development, tech transfer and manufacturing at Roivant, Novartis Vaccines and Diagnostics, Glaxo Smith Kline Vaccine, Grifols and Bristol Myers Squibb. Prior to joining Immunovant, she held various roles of increasing responsibility as a technical lead supporting CMC process development, tech transfer, manufacturing and validation, managing internal and external manufacturing and supported organizations as a member of extended leadership team utilizing innovative approaches to resolve complex issues while meeting quality, regulatory and development objectives.

Pooja holds a Master of Science degree in Biotechnology (Regulatory Affairs) from Johns Hopkins University and Bachelor of Science degree in Biotechnology (Biochemical Pharmacology) from University at Buffalo.

Steve Midgley, JD

Vice President, Associate General Counsel

Steve is a strategic legal business partner with extensive experience advising pharmaceutical organizations on commercial execution, regulatory compliance, and complex business transactions. He has provided legal and business counsel across clinical-stage to mature companies, supporting corporate governance, product launches, promotional review, and managed care engagements while leading cross-functional teams to optimize operational efficiencies. His commitment to cross-functional collaboration has been recognized across multiple organizations. Before transitioning to the pharmaceutical industry, his private practice included commercial and insurance defense litigation.

Steve holds a JD from Texas Tech University School of Law and a BBA. in Finance from Texas Christian University.

Anirban Mukherjee, MBA, MS

Vice President, Procurement

Anirban brings over 17 years of experience in global procurement and supplier management across multiple industries and roles to Immunovant. Prior to joining Immunovant, Anirban led the relationship and performance management of all outsourced suppliers across the drug development functions at Gilead Sciences. Prior to Gilead, Anirban spent nearly a dozen years with Becton Dickinson in a variety of procurement roles; including the design and implementation of global supply chains for outsourced manufacturing, and specialization in Asia Pacific and LATAM regions. His earlier experience include the Ford Motor Company, where Anirban was responsible for high-technology supplier launches, and Goodyear Tires where he was a design engineer.

Anirban earned his M.B.A and B.S. in Mechanical Engineering from the University of Pittsburgh, and an M.S. in Engineering from Youngstown State University.

Ike Ogbaa, MD

Vice President & Global Head of Medical Affairs

Ike Ogbaa, MD brings over 20 years of comprehensive experience in the clinical practice and pharmaceutical sectors. He most recently served in senior leadership positions as Vice President and Global Head of Medical Affairs at both Bluebird Bio and Chinook Therapeutics, a Novartis company. His extensive background includes progressively responsible roles in Medical Affairs at Merck, Sanofi, GlaxoSmithKline, and Bayer, where he has successfully spearheaded drug launches across diverse therapeutic areas, including Endocrinology, Hematology, Neuroscience and Immunology.

Dr. Ogbaa earned a Bachelor’s degree in Psychology with a concentration in Behavioral Neuroscience from Yale University. He holds a Medical Doctorate from Rutgers Robert Wood Johnson Medical School in Piscataway, New Jersey, and completed his Internal Medicine residency at Baylor College of Medicine in Houston, Texas. Additionally, Dr. Ogbaa is certified in Medical Affairs and Medicines Development by King’s College London, and he has completed the AI in Pharma & Biotech certification from the MIT Sloan School of Management.

Cassandra Pauyo, MS

Vice President, Data Management

Cassandra is an experienced R&D professional with a deep leadership background in Data Management operations across multiple treatment modalities, therapeutic areas, and phases of drug development. Prior to Immunovant, Cassandra has held roles of increasing responsibility, including building and leading the Data Management function, at Cubist Pharmaceuticals (now a Merck company), Akebia Therapeutics, and Albireo Pharma (now an Ipsen company) in support of successful Regulatory approvals across several compounds and indications.

Cassandra earned a B.S. in Biomedical Laboratory and Clinical Sciences from Boston University in Boston, Massachusetts. She has a Masters in Public Health from the University of Massachusetts in Amherst. In addition, Cassandra holds a Certificate in Biotechnology from Boston University and a Certificate of Clinical Data Management from the Society of Clinical Data Management.

Rod Saponjic, PhD, MBA, MS

Vice President of Clinical Operations

Rod has more than 25 years of drug development leadership experience in the areas of global operations, project management, clinical operations, clinical systems, and vendor management. Prior to Immunovant, Rod led Clinical Operations at Respivant, responsible for the management of Phase 1-3 trials in the areas of immunology and respiratory disease. Prior to Respivant, Rod led global development operations at Greenwich Bioscience, resulting in the NDA submission and the first FDA approval of a cannabinoid therapy. Prior to Greenwich, Rod has held senior management positions at Alkensa, Clingenix, Patara Pharma, PRA International, AirPharma, Quintiles, and Synteract.

Rod earned his B.A. in Psychology at Texas Tech University. He earned his M.S. and Ph.D. in Neuroscience at Texas Christian University and an M.B.A. at Baker University.

Lauren Schrier, MBA

Vice President of Marketing

Lauren brings expertise in commercial product strategy and execution in immunology. Prior to joining Immunovant, Lauren held multiple leadership roles at Celgene, including experiences spanning Global Marketing, Commercial Development, Project Leadership, and Chief of Staff for the Inflammation and Immunology franchise. Prior to Celgene, Lauren worked in management consulting at Accenture and Easton Associates, where she advised life science clients in opportunity assessment, strategy, and development engagements.

Lauren earned a B.S.E. in Chemical and Biomolecular Engineering from the University of Pennsylvania, and an M.B.A. in Healthcare and Pharmaceutical Management from Columbia Business School.

Philip Tedeschi, PhD, MS

Vice President, Translational Sciences and Clinical Laboratories

Phil is a translational scientist who brings more than 15 years of drug development knowledge for both small and large molecule programs. His expertise includes biomarkers, bioanalysis and toxicology. Prior to joining Immunovant, Phil worked at Pfizer where he led laboratory teams supporting discovery through phase 1 trials in oncology, including INDs for first-in-class therapeutics. Prior to Pfizer, Phil worked across programs of various stages in both oncology and inflammation/Immunology therapeutic areas.

Phil holds a Ph.D. in Molecular Pharmacology from Rutgers University, a M.S. in Biotechnology from Johns Hopkins University and a B.S. in Biology from The College of New Jersey.

Christine Voigt, PhD

Vice President, Clinical Research Science

Christine Voigt has held a variety of industry roles including research, regulatory affairs, and clinical development. Prior to joining Immunovant, Christine, was VP Clinical Sciences at BlueSphere Bio, an immuno-oncology company with a focus on T cell therapies. Prior to BlueSphere Bio, she led clinical strategy and development at Gemini Therapeutics. With over 10 years at CSL Behring, she had various roles including clinical lead and clinical scientist, taking a novel hemophilia treatment from pre-IND to global approvals and starting three clinical development programs in transplantation.

Christine received her BA from Wesleyan University in Molecular Biology and Biochemistry and her PhD in Microbiology from Duke University.

OUR BOARD OF DIRECTORS

Frank Torti, MD, MBA, is the Vant Chair at Roivant Sciences and Executive Chairman at Immunovant. He was the founding CEO & Chairman of Telavant from the time of its inception until its sale to Roche for $7.25B.

In his role at Roivant, Dr. Torti serves as Chairman, Executive Chairman, or CEO of the public and private biopharmaceutical companies (Vants) at Roivant and is responsible for those businesses. This group of companies has advanced over forty medicines into clinical development, produced positive phase three results in eleven consecutive clinical trials, and generated over fifteen billion dollars in value. Together these companies have delivered six FDA approvals and have brought novel medicines in dermatology, oncology, immunology, men’s and women’s health, and rare disease to millions of patients.

During the course of his career, Dr. Torti has been Chairman of the Board of fifteen companies and served on more than thirty corporate boards. He has been involved in more than $22 billion in capital formation through fundraising, partnerships, and corporate acquisitions, and companies with which he has been involved have completed approximately twenty initial public offerings and M&A transactions.

Prior to joining Roivant Dr. Torti spent over a decade at New Enterprise Associates (NEA), where he was a partner at one of the largest venture capital firms in the world. Before joining NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics, where he was involved in clinical trials research and economic evaluations of clinical trials. Dr. Torti received his BA with highest honors as a Morehead Scholar at the University of North Carolina, his MD from the University of North Carolina School of Medicine, and his MBA with distinction from Harvard Business School.

Jake Bauer, MBA, has served as a member of our Board of Directors since April 2025. Mr. Bauer has served as a Venture Partner at ARCH Venture Partners and SR One Capital Management since September 2021 and as an independent consultant working with companies in the life sciences industry since November 2020. Prior to MyoKardia, Inc.’s acquisition by Bristol Myers Squibb in November 2020, Mr. Bauer served as the Chief Business Officer of MyoKardia, Inc., a clinical stage biopharmaceutical company, beginning in 2018. Mr. Bauer has also served as the Senior Vice President, Finance and Corporate Development and Principal Financial Officer of MyoKardia, Inc. from July 2016 to July 2014. Mr. Bauer also serves on the boards of directors of Enliven Therapeutics, Attralus, Simcha Therapeutics and Dispatch Therapeutics. Mr. Bauer holds a B.Sc. in Biology and a B.A. in Economics from Duke University and an M.B.A. from Harvard Business School.

Andrew Fromkin has served as a member of our board of directors since October 2019. Since January 2021, Mr. Fromkin has served as the Vant Portfolio Operating Partner for Roivant Sciences, Inc., or RSI. From January 2021 until April 2023, Mr. Fromkin served as the Acting Chief Executive Officer of Proteovant Sciences, Inc. From March 2015 to September 2020, Mr. Fromkin served as Chief Executive Officer of Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.). From 2005 until 2011, Mr. Fromkin served in various roles for Clinical Data, Inc., including Executive Vice President (October 2005 until May 2006) and President, Chief Executive Officer and Director (May 2006 until May 2011). Prior to Clinical Data, Mr. Fromkin served as President and Chief Executive Officer of DoctorQuality, Inc., President, Chief Executive Officer and Director of Endo Surgical Devices, Inc. and Corporate Vice President, Business Development, for Merck-Medco, a wholly-owned subsidiary of Merck & Co. Mr. Fromkin began his career at Health Information Technologies, Inc. as General Manager of its subsidiary, MCA, and Director of Marketing and Payer Alliances for the parent company. From 2014 until 2016, Mr. Fromkin served on the board of Regado Biosciences, Inc. which became Tobira Therapeutics, Inc. in 2015. Mr. Fromkin received a B.A. from Brandeis University.

Douglas Hughes, MBA has served as a member of our board of directors since October 2019. Since 2018, Mr. Hughes has served as Chief Financial Officer of Calyxo Inc., an early-stage medical device company. From 2011 until 2018, Mr. Hughes was Chief Financial Officer for NeoTract, Inc., a Urology company. Prior to that time, he served as Chief Financial Officer and Chief Operating Officer for Nellix, Inc., an endovascular graft biotechnology company. Before joining Nellix, Inc., Mr. Hughes served as Chief Financial Officer for Evalve Inc., a medical device company, from 2009 until 2010. Prior to 2009, Mr. Hughes held a variety of senior finance management positions at Boston Scientific, Guidant Corporation and The Clorox Company. Mr. Hughes currently serves as a member of the board of directors of Calyxo Inc., a privately held medical device company. From September 2020 to December 2022, Mr. Hughes served as a member of the board of directors of Eargo Inc., a publicly traded medical device company. Mr. Hughes received a B.S. in Finance from San Francisco State University and an M.B.A. from the University of Chicago.

Atul Pande, MD, has served as a member of our board of directors since October 2019. Dr. Pande has extensive experience in treatment development across multiple disease areas. He is currently a board member of Karuna Therapeutics, Autifony Therapeutics, Perception Neurosciences and Pangea Botanica, and served as a board member of Sio Gene Therapies from March 2015 to April 2023. He previously served as the Chief Medical Officer of PureTech Health, Chief Medical Officer of Tal Medical, and medical advisor to PureTech Health. Since September 2016, he has also served as Chief Executive Officer of Verity BioConsulting, a drug development consulting firm that provides services to clients in the biopharmaceutical business. From 2007 to April 2014, Dr. Pande was Senior Vice President and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline. He has also held senior roles at Pfizer R&D, Parke-Davis/ Warner-Lambert and Lilly Research Laboratories. He has been on the Scientific Advisory Boards of Cennerv Pharma and Centrexion Corporation. Dr. Pande is a physician who completed his research fellowship training in psychiatry at the University of Michigan Medical School and his postgraduate specialty training and psychiatry residency program at Western University.

Robert Susman, MBA, has served as a member of our Board of Directors since April 2025. Mr. Susman is currently a Managing Director and Global Head of Equity Research for Principal Asset Management, a large asset manager within Principal Financial Group. Mr. Susman previously served as Director of Strategy at Artisan Partners, a publicly traded asset manager with over $160 billion in assets under management, from April 2023 to November 2024. His leadership role involved business development, client fundraising and managing the investment research team of one of the firm’s newest alternative investment strategies. Prior to that, from January 2013 to April 2023, Mr. Susman was a Portfolio Manager and Senior Analyst at Marsico Capital, a multi-billion dollar growth-oriented investment firm, where he co-managed the Global Fund and International Opportunities Fund. Prior to this role, Mr. Susman was an Analyst at Baron Capital and held various positions at Morgan Stanley. Mr. Susman graduated from Harvard College and Harvard Business School and is a CFA Charterholder.

Eric Venker, MD, PharmD, is the Chief Executive Officer of Immunovant and has served on the Board of Directors since 2020. He brings more than two decades of clinical practice and operating experience to the company. Dr. Venker also serves as the President and Chief Operating Officer of Roivant Sciences, a position he has held since 2018. Dr. Venker first joined Roivant in 2014 and has held various roles of increasing responsibility, including Chief Medical Officer and Chief of Staff to the CEO. Earlier in his career, Dr. Venker was a physician at New York Presbyterian Hospital, Columbia University Medical Center, where he trained in internal medicine. While there, Eric led operational initiatives to improve efficiencies across a large hospital system with $5 billion in annual revenue. Earlier in his career, Eric was a Clinical Pharmacist at Yale-New Haven Hospital. Dr. Venker received his M.D. from the Yale School of Medicine and his Pharm.D. from the St. Louis College of Pharmacy.

Fellow trailblazers

Check out our corporate presentation
Explore our opportunities here